NAV

Tulathromycin A

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tulathromycin A
DrugBank Accession Number
DB11474
Background

Tulathromycin is a macrolide antibiotic used to treat bovine respiratory disease in cattle and swine respiratory disease in pigs. It is marketed by Pfizer Inc. under the tradename Draxxin.

Type
Small Molecule
Groups
Vet approved
Structure
Similar Structures
Weight
Average: 806.092
Monoisotopic: 805.566374996
Chemical Formula
C41H79N3O12
Synonyms
  • Tulathromycin
  • Tulathromycin A
External IDs
  • CP-472,295
  • CP-472295

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcenocoumarolThe risk or severity of bleeding can be increased when Tulathromycin A is combined with Acenocoumarol.
AmbroxolThe risk or severity of methemoglobinemia can be increased when Tulathromycin A is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Tulathromycin A is combined with Articaine.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tulathromycin A.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Tulathromycin A is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Tulathromycin A is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Tulathromycin A is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Tulathromycin A is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Tulathromycin A is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Tulathromycin A is combined with Capsaicin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Draxxin

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / O-glycosyl compounds / Oxanes / Monosaccharides / Tertiary alcohols / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols / Amino acids and derivatives / Carboxylic acid esters
show 12 more
Substituents
1,2-aminoalcohol / Acetal / Alcohol / Aliphatic heteromonocyclic compound / Amine / Amino acid or derivatives / Aminoglycoside core / Azacycle / Carbonyl group / Carboxylic acid derivative
show 24 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
897A3KN7AP
CAS number
217500-96-4
InChI Key
GUARTUJKFNAVIK-QPTWMBCESA-N
InChI
InChI=1S/C41H79N3O12/c1-15-17-42-22-41(50)28(8)53-31(20-39(41,10)51-14)55-33-25(5)35(56-37-32(45)29(44(12)13)18-24(4)52-37)38(9,48)19-23(3)21-43-27(7)34(46)40(11,49)30(16-2)54-36(47)26(33)6/h23-35,37,42-43,45-46,48-50H,15-22H2,1-14H3/t23-,24-,25+,26-,27-,28+,29+,30-,31+,32-,33+,34-,35-,37+,38-,39-,40-,41+/m1/s1
IUPAC Name
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-5-[(propylamino)methyl]oxan-2-yl]oxy}-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one
SMILES
[H][C@@]1(C[C@@](C)(OC)[C@](O)(CNCCC)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C

References

General References
  1. Washburn KE, Bissett W, Fajt V, Clubb F, Fosgate GT, Libal M, Smyre KE, Cass KL: The safety of tulathromycin administration in goats. J Vet Pharmacol Ther. 2007 Jun;30(3):267-70. [Article]
  2. Morselt M: [Tulathromycin, a new antibiotic for farm animals]. Tijdschr Diergeneeskd. 2004 May 1;129(9):306-7. [Article]
  3. Clothier KA, Jordan DM, Loynachan AT, Griffith RW: Safety evaluation of tulathromycin use in the caprine species: tulathromycin toxicity assessment in goats. J Vet Pharmacol Ther. 2010 Oct;33(5):499-502. [Article]
  4. Young G, Smith GW, Leavens TL, Wetzlich SE, Baynes RE, Mason SE, Riviere JE, Tell LA: Pharmacokinetics of tulathromycin following subcutaneous administration in meat goats. Res Vet Sci. 2011 Jun;90(3):477-9. doi: 10.1016/j.rvsc.2010.06.025. Epub 2010 Jul 16. [Article]
  5. Er A, Altan F, Cetin G, Dik B, Elmas M, Yazar E: Assessment of the cardiotoxicity of tulathromycin in rabbits. Acta Vet Hung. 2011 Sep;59(3):327-35. doi: 10.1556/AVet.2011.015. [Article]
  6. Benchaoui HA, Nowakowski M, Sherington J, Rowan TG, Sunderland SJ: Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J Vet Pharmacol Ther. 2004 Aug;27(4):203-10. [Article]
  7. Van Donkersgoed J, Berg J, Hendrick S: Comparison of florfenicol and tulathromycin for the treatment of undifferentiated fever in Alberta feedlot calves. Vet Ther. 2008 Winter;9(4):275-81. [Article]
  8. Nutsch RG, Hart FJ, Rooney KA, Weigel DJ, Kilgore WR, Skogerboe TL: Efficacy of tulathromycin injectable solution for the treatment of naturally occurring Swine respiratory disease. Vet Ther. 2005 Summer;6(2):214-24. [Article]
  9. Villarino N, Brown SA, Martin-Jimenez T: Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli. Antimicrob Agents Chemother. 2012 Aug;56(8):4078-86. doi: 10.1128/AAC.00218-12. Epub 2012 May 14. [Article]
  10. Leavens TL, Tell LA, Clothier KA, Griffith RW, Baynes RE, Riviere JE: Development of a physiologically based pharmacokinetic model to predict tulathromycin distribution in goats. J Vet Pharmacol Ther. 2012 Apr;35(2):121-31. doi: 10.1111/j.1365-2885.2011.01304.x. Epub 2011 Jun 15. [Article]
ChemSpider
8008030
RxNav
1309314
ZINC
ZINC000094313254
Wikipedia
Tulathromycin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.184 mg/mLALOGPS
logP2.78ALOGPS
logP2.5Chemaxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.2Chemaxon
pKa (Strongest Basic)10.21Chemaxon
Physiological Charge3Chemaxon
Hydrogen Acceptor Count14Chemaxon
Hydrogen Donor Count7Chemaxon
Polar Surface Area200.9 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity210.7 m3·mol-1Chemaxon
Polarizability90.92 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at February 25, 2016 19:04 / Updated at June 12, 2020 16:53